ArticleCurrent medicinal chemistry2026
3D-QSAR, Molecular Docking, Molecular Dynamics Simulation, and Pharmacokinetic Prediction of 1H-Pyrazolo[3,4-d]pyrimidine Derivatives as PI3Kδ Inhibitors.
Article in Current medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe inhibition of cellular inflammatory factor secretion by phosphatidylinositol- 3-kinase δ (PI3Kδ) makes it a novel target for acute lung injury therapy. This study aimed to elucidate the structure-activity relationship of 1H pyrazolo [3, 4-d] pyrimidine derivatives as PI3Kδ inhibitors for novel drug design.
methodsIn this study, a three-dimensional quantitative conformational relationship (3DQSAR) model was constructed using COMFA and CoMSIA techniques with Sybyl X-2.0 software. In-silico ADME and toxicity predictions were also evaluated using SwissADME and pkCSM tools. Molecular docking and molecular dynamics (MD) simulations (100 ns) were conducted to confirm the interaction of the compounds with the target protein using the GROMACS 2021 software package.
resultsGood predictability was assessed using the CoMFA model (Qcv² = 0.547; Rncv² = 0.991; Rpred² = 0.996) and the best CoMSIA model (Qcv² = 0.58; Rncv² = 0.992; Rpred² = 0.994). The A, B, and C rings were the basic skeleton for the potency of the inhibitors. The hydrogen bond acceptor field, electrostatic field, and hydrophobic field significantly influenced activity. The newly designed T03 showed stable RMSD/RMSF during 100 ns MD simulations and low predicted toxicity (LD50: 1579.4 mg/kg). Molecular docking revealed that T03 formed six hydrogen bonds with PI3Kδ, exhibiting a high binding affinity of -11.6 kcal/mol. DISCUSSION: The structural features of 1H pyrazolo [3, 4-d] pyrimidine derivatives through 3D-QSAR modelling established a relationship between functional groups and their biological activity. Based on the constructed 3D-QSAR model, five novel 1H pyrazolo [3, 4- d] pyrimidine derivatives targeting PI3Kδ were designed with improved predicted activities. Furthermore, molecular docking and MD simulations demonstrated stability and revealed ligand-receptor interactions. These novel potent inhibitors were assessed for their ADMET properties.
conclusionThe 3D-QSAR model exhibits great reliability and predictive power through ADMET, molecular docking, and molecular dynamic approaches. These results would provide a valuable insight into lead optimization for new drug discovery.
Indexed as
Identifiers
42136309What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.